LYEL
VIR

ARCH Venture Partners IX, LLC

Known title: 10% OwnerCIK: 0001723174

ARCH Venture Partners IX, LLC's purchase track record

ARCH Venture Partners IX, LLC has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
3/6/2026LYEL$12.50M-46.7%-36.0%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 14, 2026

Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.

this person other insiders at LYEL

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 14, 2026

Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.

this person other insiders at VIR

Transaction History

LYEL▲ Buy$12.5M
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0
VIR▼ Sell$0

We use analytics to understand how market-wall is used. No personal data is sold.